Mitoxantrone-induced suicidal erythrocyte death

Cellular Physiology and Biochemistry

Volumn 34, Issue 5, 2014, Pages 1756-1767

  Arnold, Markus ^a   Bissinger, Rosi ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Calcium; Cell volume; Ceramide; Eryptosis; Mitoxantrone; Phosphatidylserine

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; CALCIUM ION; CERAMIDE; DICHLORODIHYDROFLUORESCEIN DIACETATE; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOXANTRONE; PHOSPHATIDYLSERINE; REACTIVE OXYGEN METABOLITE; 2',7'-DICHLORODIHYDROFLUORESCEIN; CALCIUM; FLUORESCEIN DERIVATIVE;

ARTICLE; CELL DEATH; CELL SUICIDE; CELL SURFACE; CELL VOLUME; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; FLUORESCENT ANTIBODY TECHNIQUE; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HUMAN; HUMAN CELL; OXIDATIVE STRESS; SUPERNATANT; APOPTOSIS; CELL MEMBRANE; CELL SIZE; DRUG EFFECTS; METABOLISM; MULTIPLE SCLEROSIS;

ACETYLCYSTEINE; ANNEXIN A5; APOPTOSIS; CALCIUM; CELL DEATH; CELL MEMBRANE; CELL SIZE; CERAMIDES; ERYTHROCYTES; FLUORESCEINS; HUMANS; MITOXANTRONE; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PHOSPHATIDYLSERINES; REACTIVE OXYGEN SPECIES;

EID: 84912135458     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000366376     Document Type: Article

References (103)

1. Martinelli V, Radaelli M, Straffi L, Rodegher M, Comi G: Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci 2009;30:S167-170.
2. Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G: Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2013;5:CD002127.
3. Gyan E, Damotte D, Courby S, Senecal D, Quittet P, Schmidt-Tanguy A, Banos A, Le Gouill S, Lamy T, Fontan J, Maisonneuve H, Alexis M, Dreyfus F, Tournilhac O, Laribi K, Solal-Celigny P, Arakelyan N, Cartron G, Gressin R, Group G: High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. Br J Haematol 2013;162:240-249.
4. He X, Wang J, Dou J, Yu F, Cai K, Li X, Zhang H, Gu N: Antitumor efficacy induced by a B16F10 tumor cell vaccine treated with mitoxantrone alone or in combination with reserpine and verapamil in mice. Exp Ther Med 2011;2:911-916.
5. Lee KJ, An JH, Chun JR, Chung KH, Park WY, Shin JS, Kim DH, Bahk YY: In vitro analysis of the anti-cancer activity of mitoxantrone loaded on magnetic nanoparticles. J Biomed Nanotechnol 2013;9:1071-1075.
6. Miranda E, Maya Pineda H, Oberg D, Cherubini G, Garate Z, Lemoine NR, Hallden G: Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region. PLoS One 2012;7:e46617.
7. Yagublu V, Caliskan N, Lewis AL, Jesenofsky R, Gasimova L, Lohr JM, Keese M: Treatment of experimental pancreatic cancer by doxorubicin-, mitoxantrone-, and irinotecan-drug eluting beads. Pancreatology 2013;13:79-87.
8. Zhao H, Rybak P, Dobrucki J, Traganos F, Darzynkiewicz Z: Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide. Cytometry A 2012;81:45-51.
9. Keese M, Gasimova L, Schwenke K, Yagublu V, Shang E, Faissner R, Lewis A, Samel S, Lohr M: Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer. Int J Cancer 2009;124:2701-2708.
10. Mimeault M, Mehta PP, Hauke R, Henichart JP, Depreux P, Lin MF, Batra SK: Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades. Growth Factors 2007;25:400-416.
11. Cao C, Han Y, Ren Y, Wang Y: Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-tumor immune response. Cell Mol Immunol 2009;6:469-475.
12. Dubielecka PM, Grzybek M, Kolondra A, Jazwiec B, Draga A, Aleksandrowicz P, Kolodziejczyk M, Serwotka A, Dolinska-Krajewska B, Warchol J, Kuliczkowski K, Sikorski AF: Aggregation of spectrin and PKCtheta is an early hallmark of fludarabine/mitoxantrone/dexamethasone-induced apoptosis in Jurkat T and HL60 cells. Mol Cell Biochem 2010;339:63-77.
13. Grandhi TS, Potta T, Taylor DJ, Tian Y, Johnson RH, Meldrum DR, Rege K: Sensitizing cancer cells to TRAIL-induced death by micellar delivery of mitoxantrone. Nanomedicine (Lond) 2013;10.2217/nnm.13.125
14. Kostrzewa-Nowak D, Tarasiuk J: Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase does not change its apoptotic stimuli properties in regard to sensitive and multidrug resistant leukaemia HL60 cells. Eur J Pharmacol 2013;721:141-150.
15. Li JM, Yang Y, Zhu P, Zheng F, Gong FL, Mei YW: Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells. Immunopharmacol Immunotoxicol 2012;34:36-41.
16. Li Y, Zhao L, Sun H, Yu J, Li N, Liang J, Wang Y, He M, Bai X, Yu Z, Zheng Z, Mi X, Wang E, Wei M: Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells. PLoS One 2012;7:e44254.
17. Symes JC, Kurin M, Fleshner NE, Medin JA: Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel. Mol Cancer Ther 2008;7:3018-3028.
18. Neuhaus O, Wiendl H, Kieseier BC, Archelos JJ, Hemmer B, Stuve O, Hartung HP: Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005;168:128-137.
19. Seifrtova M, Havelek R, Soukup T, Filipova A, Mokry J, Rezacova M: Mitoxantrone ability to induce premature senescence in human dental pulp stem cells and human dermal fibroblasts. J Physiol Pharmacol 2013;64:255-266.
20. Chan A, Lo-Coco F: Mitoxantrone-related acute leukemia in MS: an open or closed book? Neurology 2013;80:1529-1533.
21. Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, Tremlett H: Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 2010;74:1822-1826.
22. DiPaola RS, Chen YH, Stein M, Vaughn D, Patrick-Miller L, Carducci M, Roth B, White E, Wilding G: A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. J Transl Med 2010;8:20.
23. Font A, Murias A, Arroyo FR, Martin C, Areal J, Sanchez JJ, Santiago JA, Constenla M, Saladie JM, Rosell R: Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. Ann Oncol 2005;16:419-424.
24. Galli L, Fontana A, Galli C, Landi L, Fontana E, Antonuzzo A, Andreuccetti M, Aitini E, Barbieri R, Di Marsico R, Falcone A: Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer. Br J Cancer 2007;97:1613-1617.
25. Greidanus J, de Vries EG, Mulder NH, Sleijfer DT, Uges DR, Oosterhuis B, Willemse PH: A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. J Clin Oncol 1989;7:790-797.
26. Ho AD, Del Valle F, Engelhard M, Hiddemann W, Ruckle H, Schlimok G, Haas R, Thiel E, Andreesen R, Fiedler W, et al.: Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study. Cancer 1990;66:423-430.
27. Shepherd FA, Evans WK, Blackstein ME, Fine S, Heathcote J, Langer B, Taylor B, Habal F, Kutas G, Pritchard KI, et al.: Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. J Clin Oncol 1987;5:635-640.
28. Lang E, Qadri SM, Lang F: Killing me softly - suicidal erythrocyte death. Int J Biochem Cell Biol 2012;44:1236-1243.
29. Lang PA, Kaiser S, Myssina S, Wieder T, Lang F, Huber SM: Role of Ca2+-activated K+ channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol 2003;285:C1553-C1560.
30. Bhavsar SK, Bobbala D, Xuan NT, Foller M, Lang F: Stimulation of suicidal erythrocyte death by alpha-lipoic acid. Cell Physiol Biochem. 2010;26:859-868.
31. Foller M, Huber SM, Lang F: Erythrocyte programmed cell death. IUBMB Life 2008;60:661-668.
32. Foller M, Mahmud H, Gu S, Wang K, Floride E, Kucherenko Y, Luik S, Laufer S, Lang F: Participation of leukotriene C (4) in the regulation of suicidal erythrocyte death. J Physiol Pharmacol 2009;60:135-143.
33. Lau IP, Chen H, Wang J, Ong HC, Leung KC, Ho HP, Kong SK: In vitro effect of CTAB- and PEG-coated gold nanorods on the induction of eryptosis/erythroptosis in human erythrocytes. Nanotoxicology 2012;6:847-856.
34. Maellaro E, Leoncini S, Moretti D, Del Bello B, Tanganelli I, De Felice C, Ciccoli L: Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol 2013;50:489-495.
35. Foller M, Sopjani M, Koka S, Gu S, Mahmud H, Wang K, Floride E, Schleicher E, Schulz E, Munzel T, Lang F: Regulation of erythrocyte survival by AMP-activated protein kinase. FASEB J 2009;23:1072-1080.
36. Foller M, Feil S, Ghoreschi K, Koka S, Gerling A, Thunemann M, Hofmann F, Schuler B, Vogel J, Pichler B, Kasinathan RS, Nicolay JP, Huber SM, Lang F, Feil R: Anemia and splenomegaly in cGKI-deficient mice. Proc Natl Acad Sci USA 2008;105:6771-6776.
37. Zelenak C, Foller M, Velic A, Krug K, Qadri SM, Viollet B, Lang F, Macek B: Proteome analysis of erythrocytes lacking AMP-activated protein kinase reveals a role of PAK2 kinase in eryptosis. J Proteome Res 2011;10:1690-1697.
38. Lupescu A, Shaik N, Jilani K, Zelenak C, Lang E, Pasham V, Zbidah M, Plate A, Bitzer M, Foller M, Qadri SM, Lang F: Enhanced Erythrocyte Membrane Exposure of Phosphatidylserine Following Sorafenib Treatment: An in vivo and in vitro Study. Cell Physiol Biochem 2012;30:876-888.
39. Shaik N, Lupescu A, Lang F: Sunitinib-sensitive suicidal erythrocyte death. Cell Physiol Biochem 2012;30:512-522.
40. Kucherenko Y, Zelenak C, Eberhard M, Qadri SM, Lang F: Effect of casein kinase 1alpha activator pyrvinium pamoate on erythrocyte ion channels. Cell Physiol Biochem 2012;30:407-417.
41. Zelenak C, Eberhard M, Jilani K, Qadri SM, Macek B, Lang F: Protein kinase CK1alpha regulates erythrocyte survival. Cell Physiol Biochem 2012;29:171-180.
42. Bhavsar SK, Gu S, Bobbala D, Lang F: Janus kinase 3 is expressed in erythrocytes, phosphorylated upon energy depletion and involved in the regulation of suicidal erythrocyte death. Cell Physiol Biochem 2011;27:547-556.
43. Klarl BA, Lang PA, Kempe DS, Niemoeller OM, Akel A, Sobiesiak M, Eisele K, Podolski M, Huber SM, Wieder T, Lang F: Protein kinase C mediates erythrocyte "programmed cell death" following glucose depletion. Am J Physiol Cell Physiol 2006;290:C244-C253.
44. Gatidis S, Zelenak C, Fajol A, Lang E, Jilani K, Michael D, Qadri SM, Lang F: p38 MAPK activation and function following osmotic shock of erythrocytes. Cell Physiol Biochem 2011;28:1279-1286.
45. Sinha A, Singh A, Satchidanandam V, Natarajan K: Impaired generation of reactive oxygen species during differentiation of dendritic cells (DCs) by Mycobacterium tuberculosis secretory antigen (MTSA) and subsequent activation of MTSA-DCs by mycobacteria results in increased intracellular survival. J Immunol 2006;177:468-478.
46. Canal P, Attal M, Chatelut E, Guichard S, Huguet F, Muller C, Schlaifer D, Laurent G, Houin G, Bugat R: Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. Cancer Res 1993;53:4850-4854.
47. Abed M, Towhid ST, Mia S, Pakladok T, Alesutan I, Borst O, Gawaz M, Gulbins E, Lang F: Sphingomyelinaseinduced adhesion of eryptotic erythrocytes to endothelial cells. Am J Physiol Cell Physiol 2012;303:C991-999.
48. Bottger E, Multhoff G, Kun JF, Esen M: Plasmodium falciparum-infected erythrocytes induce granzyme B by NK cells through expression of host-Hsp70. PLoS One 2012;7:e33774.
49. Firat U, Kaya S, Cim A, Buyukbayram H, Gokalp O, Dal MS, Tamer MN: Increased caspase-3 immunoreactivity of erythrocytes in STZ diabetic rats. Exp Diabetes Res 2012;2012:316384.
50. Ganesan S, Chaurasiya ND, Sahu R, Walker LA, Tekwani BL: Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: evaluation of eryptotic pathway. Toxicology 2012;294:54-60.
51. Gao M, Cheung KL, Lau IP, Yu WS, Fung KP, Yu B, Loo JF, Kong SK: Polyphyllin D induces apoptosis in human erythrocytes through Ca (2) (+) rise and membrane permeabilization. Arch Toxicol 2012;86:741-752.
52. Ghashghaeinia M, Cluitmans JC, Akel A, Dreischer P, Toulany M, Koberle M, Skabytska Y, Saki M, Biedermann T, Duszenko M, Lang F, Wieder T, Bosman GJ: The impact of erythrocyte age on eryptosis. Br J Haematol 2012;157:606-614.
53. Jilani K, Lupescu A, Zbidah M, Abed M, Shaik N, Lang F: Enhanced Apoptotic Death of Erythrocytes Induced by the Mycotoxin Ochratoxin A. Kidney Blood Press Res 2012;36:107-118.
54. Jilani K, Lupescu A, Zbidah M, Shaik N, Lang F: Withaferin A-stimulated Ca2+ entry, ceramide formation and suicidal death of erythrocytes. Toxicol In Vitro 2013;27:52-58.
55. Kucherenko YV, Lang F: Inhibitory Effect of Furosemide on Non-Selective Voltage-Independent Cation Channels in Human Erythrocytes. Cell Physiol Biochem 2012;30:863-875.
56. Lang E, Jilani K, Zelenak C, Pasham V, Bobbala D, Qadri SM, Lang F: Stimulation of suicidal erythrocyte death by benzethonium. Cell Physiol Biochem 2011;28:347-354.
57. Lang E, Qadri SM, Jilani K, Zelenak C, Lupescu A, Schleicher E, Lang F: Carbon monoxide-sensitive apoptotic death of erythrocytes. Basic Clin Pharmacol Toxicol 2012;111:348-355.
58. Lupescu A, Jilani K, Zbidah M, Lang E, Lang F: Enhanced Ca (2+) Entry, Ceramide Formation, and Apoptotic Death of Erythrocytes Triggered by Plumbagin. J Nat Prod 2012;10.1021/np300611r
59. Lupescu A, Jilani K, Zbidah M, Lang F: Induction of apoptotic erythrocyte death by rotenone. Toxicology 2012;300:132-137.
60. Polak-Jonkisz D, Purzyc L: Ca Influx versus Efflux during Eryptosis in Uremic Erythrocytes. Blood Purif 2012;34:209-210.
61. Qian EW, Ge DT, Kong SK: Salidroside protects human erythrocytes against hydrogen peroxide-induced apoptosis. J Nat Prod 2012;75:531-537.
62. Shaik N, Zbidah M, Lang F: Inhibition of Ca (2+) entry and suicidal erythrocyte death by naringin. Cell Physiol Biochem 2012;30:678-686.
63. Vota DM, Maltaneri RE, Wenker SD, Nesse AB, Vittori DC: Differential erythropoietin action upon cells induced to eryptosis by different agents. Cell Biochem Biophys 2013;65:145-157.
64. Weiss E, Cytlak UM, Rees DC, Osei A, Gibson JS: Deoxygenation-induced and Ca (2+) dependent phosphatidylserine externalisation in red blood cells from normal individuals and sickle cell patients. Cell Calcium 2012;51:51-56.
65. Zappulla D: Environmental stress, erythrocyte dysfunctions, inflammation, and the metabolic syndrome: adaptations to CO2 increases? J Cardiometab Syndr 2008;3:30-34.
66. Zbidah M, Lupescu A, Jilani K, Lang F: Stimulation of suicidal erythrocyte death by fumagillin. Basic Clin Pharmacol Toxicol 2013;112:346-351.
67. Zbidah M, Lupescu A, Shaik N, Lang F: Gossypol-induced suicidal erythrocyte death. Toxicology 2012;302:101-105.
68. Zelenak C, Pasham V, Jilani K, Tripodi PM, Rosaclerio L, Pathare G, Lupescu A, Faggio C, Qadri SM, Lang F: Tanshinone IIA stimulates erythrocyte phosphatidylserine exposure. Cell Physiol Biochem 2012;30:282-294.
69. Abed M, Herrmann T, Alzoubi K, Pakladok T, Lang F: Tannic Acid induced suicidal erythrocyte death. Cell Physiol Biochem 2013;32:1106-1116.
70. Ahmed MS, Langer H, Abed M, Voelkl J, Lang F: The uremic toxin acrolein promotes suicidal erythrocyte death. Kidney Blood Press Res 2013;37:158-167.
71. Ghashghaeinia M, Cluitmans JC, Toulany M, Saki M, Koberle M, Lang E, Dreischer P, Biedermann T, Duszenko M, Lang F, Bosman GJ, Wieder T: Age Sensitivity of NFkappaB Abundance and Programmed Cell Death in Erythrocytes Induced by NFkappaB Inhibitors. Cell Physiol Biochem 2013;32:801-813.
72. Lupescu A, Jilani K, Zbidah M, Lang F: Patulin-induced suicidal erythrocyte death. Cell Physiol Biochem 2013;32:291-299.
73. Voelkl J, Alzoubi K, Mamar AK, Ahmed MS, Abed M, Lang F: Stimulation of suicidal erythrocyte death by increased extracellular phosphate concentrations. Kidney Blood Press Res 2013;38:42-51.
74. Calderon-Salinas JV, Munoz-Reyes EG, Guerrero-Romero JF, Rodriguez-Moran M, Bracho-Riquelme RL, Carrera-Gracia MA, Quintanar-Escorza MA: Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease. Mol Cell Biochem 2011;357:171-179.
75. Nicolay JP, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G Jr, Thornalley PJ, Schleicher E, Wieder T, Lang F: Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem 2006;18:223-232.
76. Abed M, Feger M, Alzoubi K, Pakladok T, Frauenfeld L, Geiger C, Towhid ST, Lang F: Sensitization of erythrocytes to suicidal erythrocyte death following water deprivation. Kidney Blood Press Res 2013;37:567-578.
77. Myssina S, Huber SM, Birka C, Lang PA, Lang KS, Friedrich B, Risler T, Wieder T, Lang F: Inhibition of erythrocyte cation channels by erythropoietin. J Am Soc Nephrol 2003;14:2750-2757.
78. Abed M, Artunc F, Alzoubi K, Honisch S, Baumann D, Foller M, Lang F: Suicidal erythrocyte death in endstage renal disease. J Mol Med (Berl) 2014;10.1007/s00109-014-1151-4
79. Lang PA, Beringer O, Nicolay JP, Amon O, Kempe DS, Hermle T, Attanasio P, Akel A, Schafer R, Friedrich B, Risler T, Baur M, Olbricht CJ, Zimmerhackl LB, Zipfel PF, Wieder T, Lang F: Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med (Berl) 2006;84:378-388.
80. Kempe DS, Akel A, Lang PA, Hermle T, Biswas R, Muresanu J, Friedrich B, Dreischer P, Wolz C, Schumacher U, Peschel A, Gotz F, Doring G, Wieder T, Gulbins E, Lang F: Suicidal erythrocyte death in sepsis. J Mol Med 2007;85:269-277.
81. Foller M, Bobbala D, Koka S, Huber SM, Gulbins E, Lang F: Suicide for survival-death of infected erythrocytes as a host mechanism to survive malaria. Cell Physiol Biochem. 2009;24:133-140.
82. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F: Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007;13:164-170.
83. Kempe DS, Lang PA, Duranton C, Akel A, Lang KS, Huber SM, Wieder T, Lang F: Enhanced programmed cell death of iron-deficient erythrocytes. FASEB J 2006;20:368-370.
84. Qadri SM, Mahmud H, Lang E, Gu S, Bobbala D, Zelenak C, Jilani K, Siegfried A, Foller M, Lang F: Enhanced suicidal erythrocyte death in mice carrying a loss-of-function mutation of the adenomatous polyposis coli gene. J Cell Mol Med 2012;16:1085-1093.
85. Birka C, Lang PA, Kempe DS, Hoefling L, Tanneur V, Duranton C, Nammi S, Henke G, Myssina S, Krikov M, Huber SM, Wieder T, Lang F: Enhanced susceptibility to erythrocyte "apoptosis" following phosphate depletion. Pflugers Arch 2004;448:471-477.
86. Albertsson P, Lennernas B, Norrby K: Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis. APMIS 2012;120:147-156.
87. Rossato LG, Costa VM, Vilas-Boas V, de Lourdes Bastos M, Rolo A, Palmeira C, Remiao F: Therapeutic concentrations of mitoxantrone elicit energetic imbalance in h9c2 cells as an earlier event. Cardiovasc Toxicol 2013;13:413-425.
88. Vibet S, Maheo K, Gore J, Dubois P, Bougnoux P, Chourpa I: Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos 2007;35:822-828.
89. Adamczyk-Sowa M, Sowa P, Pierzchala K, Polaniak R, Labuz-Roszak B: Antioxidative enzymes activity and malondialdehyde concentration during mitoxantrone therapy in multiple sclerosis patients. J Physiol Pharmacol 2012;63:683-690.
90. Jamroz-Wisniewska A, Beltowski J, Stelmasiak Z, Bartosik-Psujek H: Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy. Acta Neurol Scand 2013;127:e33-36.
91. Lang F, Abed M, Lang E, Foller M: Oxidative stress and suicidal erythrocyte death. Antioxid Redox Signal 2014;21:138-153.
92. Bettaieb A, Plo I, Mansat-De Mas V, Quillet-Mary A, Levade T, Laurent G, Jaffrezou JP: Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramide generation and apoptosis. Mol Pharmacol 1999;55:118-125.
93. Lang F, Gulbins E, Lang PA, Zappulla D, Foller M: Ceramide in suicidal death of erythrocytes. Cell Physiol Biochem 2010;26:21-28.
94. Lang PA, Kempe DS, Tanneur V, Eisele K, Klarl BA, Myssina S, Jendrossek V, Ishii S, Shimizu T, Waidmann M, Hessler G, Huber SM, Lang F, Wieder T: Stimulation of erythrocyte ceramide formation by plateletactivating factor. J Cell Sci 2005;118:1233-1243.
95. Harrison HE, Bunting H, Ordway NK, Albrink WS: The Pathogenesis of the Renal Injury Produced in the Dog by Hemoglobin or Methemoglobin. J Exp Med 1947;86:339-356.
96. Borst O, Abed M, Alesutan I, Towhid ST, Qadri SM, Foller M, Gawaz M, Lang F: Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol 2012;302:C644-C651.
97. Andrews DA, Low PS: Role of red blood cells in thrombosis. Curr. Opin. Hematol. 1999;6:76-82.
98. Closse C, Dachary-Prigent J, Boisseau MR: Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 1999;107:300-302.
99. Gallagher PG, Chang SH, Rettig MP, Neely JE, Hillery CA, Smith BD, Low PS: Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood 2003;101:4625-4627.
100. Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Di Silvestre S, Amoroso L, Di Tomo P, Capani F, Consoli A, Bonomini M: Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 2007;213:699-709.
101. Wood BL, Gibson DF, Tait JF: Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flowcytometric measurement and clinical associations. Blood 1996;88:1873-1880.
102. Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH: Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 2007;27:414-421.
103. Zwaal RF, Comfurius P, Bevers EM: Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005;62:971-988.